The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials.
- DOI
- 10.1038/s41467-024-53384-1
- Published
- 2024-10-25
- Container
- Nat Commun
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41467-024-53384-1,
title = {The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials.},
author = {Silverberg JI and Rosmarin D and Chovatiya R and Bieber T and Schleicher S and Beck L and Gooderham M and Chaudhry S and Fanton C and Yu D and Levy J and Liu Y and Miyazaki T and Tagliaferri M and Schmitz C and Nirula A and Kotzin B and Zalevsky J.},
year = {2024},
journal = {Nat Commun},
doi = {10.1038/s41467-024-53384-1},
url = {https://doi.org/10.1038/s41467-024-53384-1}
}RIS
TY - JOUR TI - The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials. AU - Silverberg JI AU - Rosmarin D AU - Chovatiya R AU - Bieber T AU - Schleicher S AU - Beck L AU - Gooderham M AU - Chaudhry S AU - Fanton C AU - Yu D AU - Levy J AU - Liu Y AU - Miyazaki T AU - Tagliaferri M AU - Schmitz C AU - Nirula A AU - Kotzin B AU - Zalevsky J. PY - 2024 JO - Nat Commun DO - 10.1038/s41467-024-53384-1 UR - https://doi.org/10.1038/s41467-024-53384-1 ER -
APA
JI, S., D, R., R, C., T, B., S, S., L, B., M, G., S, C., C, F., D, Y., J, L., Y, L., T, M., M, T., C, S., A, N., B, K., & J., Z. (2024). The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials.. Nat Commun. https://doi.org/10.1038/s41467-024-53384-1
Source records
- europe-pmc · retrieved 2026-09-27T08:39:24.823Z
- doaj · retrieved 2026-09-27T08:39:24.847Z